07:00 Mon 30 Nov 2020
Immupharma PLC - Total Share Capital Notification
RNS | eCorporate
ImmuPharma PLC
("ImmuPharma" or the "Company")
Total Share Capital Notification
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that in accordance with its obligations to the Company's Euronext listing and following an application of Article 15 of the Belgian Law of
| Situation as at |
|
|
|
1. Information to be provided for on the basis of Article 15, §1, al. 1
|
|
|
| Total of share capital (nominal value) | : | |
|
|
|
|
| Total number of shares with existing voting rights (= denominator) - one vote per share | : | 250,221,297 |
|
|
|
|
| 2. Additional information to be provided on the basis of Article 15, §1, al. 2
In respect to the announcement on |
|
|
|
|
|
|
| Convertible Securities (in whole or in part) into ordinary shares currently outstanding. The total conversion would result in an equal number of voting rights | : | 6,493,506 |
|
|
|
|
| Share options (in whole or in part) The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights
| : | 25,640,254 |
| In respect to the announcements on |
|
|
|
|
|
|
| Warrants over ordinary shares (in whole or in part) The exercise of the warrants would result in the creation of an equal number of ordinary shares and voting rights
In respect to the announcement on
Share options (in whole or in part) The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights
| :
: | 3,343,045
9,625,000 |
|
|
|
|
|
|
|
|
| Other outstanding rights to subscribe ordinary shares as detailed in the Annual Report 2019 (Report and consolidated financial Statements for the year ended |
|
|
|
|
|
|
| Share options (in whole or in part) The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights | : | 16,368,850 |
|
|
|
|
This situation (the denominator) serves as a basis for the notification of major holdings by shareholders.
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
